Mithramycin A activates Fas death pathway in leukemic cell lines

Apoptosis

Volumn 11, Issue 1, 2006, Pages 113-119

  Leroy, I ^a   Laurent, G ^a   Quillet Mary, A ^a,b  

^a France   (France)

^b CHU PURPAN   (France)

Author keywords

Apoptosis; c Flip; Fas; Mithramycin A

Indexed keywords

ANTIINFECTIVE AGENT; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; MITHRAMYCIN;

APOPTOSIS; ARTICLE; CELL SURFACE; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; LETHALITY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG RESISTANCE, NEOPLASM; FAS LIGAND PROTEIN; HUMANS; JURKAT CELLS; LEUKEMIA; PLICAMYCIN; SIGNAL TRANSDUCTION;

EID: 31444454349     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-005-3089-z     Document Type: Article

References (39)

1. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
2. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995; 14: 5579-5588.
3. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-815.
4. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Embo J 1997; 16: 2794-2804.
5. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185-193.
6. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
7. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. Embo J 2002; 21: 3704-3714.
8. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999; 274: 7987-7992.
9. Massart C, Barbet R, Genetet N, Gibassier J. Doxorubicin induces Fas-mediated apoptosis in human Thyroid carcinoma cells. Thyroid 2004; 14: 263-270.
10. Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 1986; 315: 1433-1438.
11. Sampi K, Hozumi M, Kumai R, Honma Y, Sakurai M. Differentiation of blasts from patients in myeloid crisis of chronic myelogenous leukemia by in-vivo and in-vitro plicamycin treatment. Leuk Res 1987; 11: 1089-1092.
12. Queisser W, Herrmann F, Lindemann A, Anger B, Hiddemann W, Krey U. Therapy of the blast phase of chronic granulocytic leukemia with mithramycin and hydroxyurea. Onkologie 1988; 11: 145-146.
13. Archimbaud E, Troncy J, Sebban C, et al. Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. Cancer Chemother Pharmacol 1989; 25: 223-225.
14. Johnson PR, Yin JA, Narayanan MN, Geary CG, Love EM, Cinkotai KI. Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: a report on nine patients and review of the literature. Hematol Oncol 1991; 9: 9-15.
15. Dutcher JP, Coletti D, Paietta E, Wiernik PH. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res 1997; 21: 375-380.
16. Miller DM, Polansky DA, Thomas SD, et al. Mithramycin selectively inhibits transcription of G-C containing DNA. Am J Med Sci 1987; 294: 388-394.
17. Tagashira M, Kitagawa T, Isonishi S, Okamoto A, Ochiai K, Ohtake Y. Mithramycin represses MDR1 gene expression in vitro, modulating multidrug resistance. Biol Pharm Bull 2000; 23: 926-929.
18. Ray R, Thomas S, Miller DM. Mithramycin selectively inhibits the transcriptional activity of a transfected human c-myc gene. Am J Med Sci 1990; 300: 203-208.
19. Campbell VW, Davin D, Thomas S, et al. The G-C specific DNA binding drug, mithramycin, selectively inhibits transcription of the C-MYC and C-HA-RAS genes in regenerating liver. Am J Med Sci 1994; 307: 167-172.
20. Duverger V, Murphy AM, Sheehan D, et al. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br J Cancer 2004; 90: 2025-2031.
21. Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol 1999; 162: 7350-7357.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
23. Bailly JD, Muller C, Jaffrezou JP, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid Leukemia cell lines. Leukemia 1995; 9: 799-807.
24. Schraven B, Peter ME. APO-1(CD95)-mediated apoptosis in Jurkat cells does not involve src kinases or CD45. FEBS Lett 1995; 368: 491-494.
25. Sweeney EA, Inokuchi J, Igarashi Y. Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide. FEBS Lett 1998; 425: 61-65.
26. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 2001; 20: 1852-1859.
27. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277: 45162-45171.
28. de Thonel A, Bettaieb A, Jean C, Laurent G, Quillet-Mary A. Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells. Blood 2001; 98: 3770-3777.
29. Ross DD. Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia. Curr Opin Oncol 1991; 3: 21-29.
30. Bailly JD, Skladanowski A, Bettaieb A, Mansat V, Larsen AK, Laurent G. Natural resistance of acute myeloid Leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia 1997; 11: 1523-1532.
31. Bruno AP, Lautier D, d'Orgeix AT, Laurent G, Quillet-Mary A. Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: Implication of granzyme B and perforin. Blood 2000; 96: 1914-1920.
32. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996; 271: 4961-4965.
33. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389-406.
34. Feldmann G, Lamboley C, Moreau A, Bringuier A. Fas-mediated apoptosis of hepatic cells. Biomed Pharmacother 1998; 52: 378-385.
35. Scaffidi C, Kirchhoff S, Krammer PH, Peter ME. Apoptosis signaling in lymphocytes. Curr Opin Immunol 1999; 11: 277-285.
36. Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003; 100: 7797-7802.
37. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
38. Schuchmann M, Varfolomeev EE, Hermann F, et al. Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure. Hepatology 2003; 37: 129-135.
39. Tourneur L, Delluc S, Levy V, et al. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res 2004; 64: 8101-8108.